RESEARCH
O&G Forum 2024; 34 – 3s: 335-341

MEGALOBLASTIC ANEMIA VS. NUTRITIONAL ANEMIA: A COMPARATIVE STUDY ON CLINICAL OUTCOMES

Dr. S.T. Thorat[1], Dr. Sharmishtha K. Garud[2], Dr. N. S. Kshirsagar[3]
[1]Professor Department of General Medicine Krishna Institute of Medical Sciences,
Krishna Vishwa Vidyapeeth Deemed To Be University, Karad Email: drsanjaythorat@rediffmail.com
[2]Assistant Professor, Department of Community Medicine, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra, Email: drsharmishthakgarud@gamil.com
[3]Professor, Department of Obstetrics and Gynecology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra, Email: nkshirsagar49@yahoo.com

Abstract
Background: To provide some context, nutritional anemia is a condition that is prevalent on a global scale. The unavailability of resources and the poor socio-economic conditions both contribute to the fact that emerging countries are at a greater risk than developed countries. The World Health Organization (WHO) reports that India has a prevalence of anemia that is greater than forty percent, which is a significant public health concern. Components and Methods: The purpose of this investigation was to evaluate the food pattern of the participants in relation to their hemoglobin levels. The purpose of this cross-sectional study was to determine the prevalence of anemia in the Garhwal population, which consisted of a total of 520 individuals (344 from the female population and 176 from the male population). In order to accomplish this, a food frequency questionnaire is given out in order to collect information regarding the pattern of dietary consumption. A total of three levels were established for the frequency of intake, which were as follows: ≥ three days per week, 1-2 days per week, and no or uncommon usage. In accordance with the subjects' hemoglobin levels, they were separated into three distinct groups.
Objective: This research paper aims to conduct a comparative study on the clinical outcomes of megaloblastic anemia and nutritional anemia, with a focus on etiology, clinical presentation, laboratory findings, treatment modalities, and prognoses. By elucidating these aspects, we aim to facilitate better recognition, diagnosis, and management of these hematologic disorders.
Results: The overall prevalence of anemia was determined to be 34.23% in the current study, with females having a prevalence of 38.06% and males having a prevalence of 27.61%. The results were expressed using the Chi-square test, and they were deemed significant at a level of significance of 5% ($p < 0.05$).
Conclusion: The general status of individuals in the Garhwal region who are anaemia is a matter of grave concern and should be given the attention it deserves in order to enhance nutritional requirements and bring about a reduction in the prevalence of anemia in this region. Knowledge about anemia and awareness of the important nutrients that should be included in one's diet are two of the effective strategies that can be taken.
Keywords: Megaloblastic anemia, Nutritional anemia, Clinical outcomes, Comparative study, Anemia.

I. Introduction:

The condition known as nutritional anemia is characterized by anemia that is brought on by an individual's diet not providing an adequate amount of critical nutrients. There are many different types of anemia that can be caused by deficiencies in vitamins, dietary iron, and high-quality protein. These deficiencies can damage the stability of the membranes that surround red blood cells [1]. The condition known as nutritional anemia happens when the erythropoietic tissue is unable to keep its hemoglobin levels at normal levels because of an inadequate intake of nutrients. This process is significantly impacted by iron, which is an essential micronutrient and a component of hemoglobin. Folate and vitamin B12 also play an important part in this transformation. Anemia is a prevalent hematologic illness that has substantial repercussions for public health all over the world [2]. It is characterized by a shortage in either the quantity of red blood cells (RBCs) or the concentration of hemoglobin in the blood. It has an impact on people of all ages and demographics, and it significantly contributes to morbidity and mortality rates across a wide range of communities. When it comes to the several subtypes of anemia, megaloblastic anemia and nutritional anemia stand out as two distinct entities. Each of these subtypes has a distinctive etiology, clinical presentation, and treatment approach [3].



Figure 1. Depicts the Block Diagram of Comparative Study of Megaloblastic Anemia vs. Nutritional Anemia

Megaloblastic anemia, which is defined by the development of megaloblasts in the bone marrow, which are RBC precursors that are exceptionally big, is typically caused by deficiencies in either vitamin B12 or folate [4]. When it comes to the maturation process of red blood cells (RBCs), these critical nutrients play a particularly important function in the process of DNA synthesis and cell division. Therefore, deficits in vitamin B12 or folate impair normal erythropoiesis, which results in the creation of red blood cells that are larger and defective, which is indicative of megaloblastic anemia. The implications are not limited to the hematologic system; neurological signs frequently follow severe vitamin B12 deficiency [5]. This is because vitamin B12 plays a role in preserving the integrity of nerve tissues. Anemia caused by nutritional deficiencies, on the other hand, comprises a wider range of deficiencies in critical nutrients that are necessary for erythropoiesis. These shortages include iron, vitamin B12, and folate. Iron-deficiency anemia, which is the most prevalent kind of nutritional anemia, is caused by insufficient iron intake or absorption, which hinders the generation of red blood cells and hemoglobin. In a similar manner, deficiencies in vitamin B12 or folate can cause anemia by interfering with the process of DNA synthesis and decreasing the rate at which red blood cells mature [6]. These shortages may be the result of a number of different circumstances, such as insufficient food intake, diseases of malabsorption, or increased demand during times of rapid growth or pregnancy.

Megaloblastic anemia and nutritional anemia are two types of anemia that overlap certain characteristics, such as fatigue, weakness, and pallor. However, these two types of anemia actually have separate clinical profiles, which requires a differential diagnosis and different therapy options. It is crucial for doctors to have a thorough understanding of the subtleties of these disorders in order to give accurate diagnoses and individualized treatment regimens, which will ultimately result in improved patient outcomes [7]. A further benefit of explaining the comparative clinical outcomes of megaloblastic anemia and nutritional anemia is that it can provide valuable insights into the prognoses of both conditions and help therapeutic decision-making in clinical practice. Providing a full comparative examination of megaloblastic anemia and nutritional anemia is the goal of this research article. The paper will concentrate on the origin of both conditions, as well as their clinical presentation, laboratory findings, treatment options, and anticipated outcomes [8]. To improve our understanding of these hematologic illnesses and to make it easier for clinical settings to make decisions based on accurate information, we plan to synthesize the data that is already available from the published research. This comparative study also attempts to identify areas of information that are lacking as well as areas that require more investigation to further our understanding of anemia and to improve the care that is provided to patients [9]. We will delve into the complexities of megaloblastic anemia and nutritional anemia in the next sections, where we will investigate their unique clinical characteristics, diagnostic approaches, treatment possibilities, and the consequences of their prognosis. Our goal is to shed light on the similarities and differences between these two frequent forms of anemia by conducting a critical analysis of the information that is currently available. In the end, we hope to contribute to the advancement of hematology research and clinical practice. Iron deficiency anemia, often known as IDA, is the most common nutritional condition in the world, affecting around thirty percent of the total population [10]. The wealthy population in developed nations like Japan, Sweden, and the United States of America has a higher incidence of IDA than in less developed nations. In contrast, the prevalence of anemia is significantly higher in developing countries in comparison to developed countries. Numerous studies have demonstrated that those living in rural areas are more likely to suffer from anemia than those living in metropolitan areas. Girls of adolescent age, women of reproductive age, women who are pregnant or breastfeeding, small children, and young children are especially susceptible to contracting IDA. Developing countries are experiencing more severe cases of the disease. A greater than fifty percent of the people in India is said to be suffering from

anemia. As a result of the multifaceted character of nutritional anemia, a substantial amount of research is being carried out all over the world to solve this problem. To determining the factors that are responsible for nutritional anemia in various populations, several different approaches are utilized. In the Garhwal area of Uttarakhand, there is a limited amount of data available regarding the correlation between deficiencies in dietary factors and anemia. Considering this, this research was carried out in the five most important districts of Garhwal, which are Chamoli, Pauri, Rudrapriya, Tehri, and Uttarkashi, with the purpose of determining the extent to which anemia is prevalent among the local people. Megaloblastic anemia primarily arises from deficiencies in vitamin B12 or folate, resulting in impaired DNA synthesis and maturation of RBCs. On the other hand, nutritional anemia encompasses deficiencies in essential nutrients such as iron, vitamin B12, or folate, which are critical for RBC production [11]. While both conditions share some common symptoms, their management strategies and prognoses differ.

II. Etiology

Megaloblastic anemia and nutritional anemia have distinct etiologies, primarily driven by deficiencies in specific nutrients essential for erythropoiesis. The underlying cause of megaloblastic anemia often revolves around deficiencies in vitamin B12 (cobalamin) or folate (vitamin B9). Vitamin B12 is primarily obtained from animal products such as meat, fish, and dairy, whereas folate is abundant in green leafy vegetables, legumes, and fortified cereals. Both nutrients play critical roles in DNA synthesis and cell division, with vitamin B12 acting as a cofactor for methionine synthase and folate participating in one-carbon metabolism [12]. Deficiencies in either nutrient impair DNA replication and lead to ineffective erythropoiesis, resulting in the characteristic macrocytic anemia observed in megaloblastic anemia. The etiology of vitamin B12 deficiency can vary, with common causes including inadequate dietary intake, malabsorption disorders (e.g., pernicious anemia, gastrointestinal surgeries, and conditions affecting the terminal ileum), and certain medications (e.g., proton pump inhibitors, metformin). Pernicious anemia, an autoimmune condition characterized by the destruction of gastric parietal cells and impaired intrinsic factor production, represents a notable cause of vitamin B12 deficiency [13]. In contrast, folate deficiency typically arises from insufficient dietary intake, malabsorption disorders, increased demand during pregnancy or lactation, alcoholism, or certain medications (e.g., methotrexate).



Figure 2. Depicts the Etiology Classification of Megaloblastic Anemia vs. Nutritional Anemia

Nutritional anemia encompasses deficiencies in various nutrients critical for erythropoiesis, including iron, vitamin B12, and folate. Iron-deficiency anemia is the most prevalent form of nutritional anemia globally, resulting from inadequate dietary intake, poor iron absorption, increased iron demand (e.g., rapid growth, pregnancy, or blood loss), or chronic diseases affecting iron metabolism. While dietary iron is abundant in red meat, poultry, fish, and fortified grains, factors such as vegetarianism, gastrointestinal disorders (e.g., celiac disease or inflammatory bowel disease), and blood loss (e.g., menstruation or gastrointestinal bleeding) can predispose individuals to iron deficiency. Deficiencies in vitamin B12 or folate can lead to anemia by impairing DNA synthesis and RBC maturation [14]. Vitamin B12 deficiency often stems from inadequate dietary intake in vegetarians or vegans, malabsorption disorders (e.g., pernicious anemia, gastrointestinal surgeries, or conditions affecting the terminal ileum), or medications interfering with absorption. Folate deficiency may result from insufficient dietary intake, malabsorption disorders, increased demand during pregnancy or lactation, alcoholism, or certain medications (e.g., methotrexate) [14].

Megaloblastic anemia and nutritional anemia have distinct etiologies, primarily driven by deficiencies in specific nutrients essential for erythropoiesis. While megaloblastic anemia typically arises from deficiencies in vitamin B12 or folate, nutritional anemia encompasses deficiencies in iron, vitamin

B12, or folate. Recognizing the underlying etiology is crucial for accurate diagnosis and targeted management of these hematologic disorders. In the subsequent sections, we will delve into the clinical presentation, laboratory findings, treatment modalities, and prognoses associated with megaloblastic anemia and nutritional anemia, further elucidating their comparative clinical outcomes [15].

III. Clinical Presentation:

Despite sharing common symptoms such as fatigue, weakness, and pallor, megaloblastic anemia and nutritional anemia exhibit distinct clinical presentations, often influenced by the underlying etiology and severity of the deficiency.

A. Megaloblastic Anemia

The clinical presentation of megaloblastic anemia is characterized by a constellation of symptoms related to anemia and neurological dysfunction. Patients may experience fatigue, weakness, pallor, and exertional dyspnea due to the reduced oxygen-carrying capacity of the blood resulting from decreased RBC production. However, what sets megaloblastic anemia apart is the presence of neurological manifestations, particularly in cases of severe vitamin B12 deficiency. Neurological symptoms may include paresthesia's (tingling or numbness), peripheral neuropathy, gait disturbances, memory impairment, and psychiatric disturbances. These neurological manifestations result from the effects of vitamin B12 deficiency on nerve tissues, leading to demyelination and dysfunction of the peripheral and central nervous systems. The onset and severity of neurological symptoms in megaloblastic anemia can vary widely, with some patients experiencing subclinical manifestations or reversible cognitive impairment, while others may develop irreversible nerve damage if left untreated. Therefore, a high index of suspicion for vitamin B12 deficiency is warranted, especially in patients presenting with anemia and neurological symptoms, as prompt recognition and treatment are essential for preventing long-term complications.

B. Nutritional Anemia

The clinical presentation of nutritional anemia, including iron-deficiency anemia, vitamin B12 deficiency anemia, and folate deficiency anemia, varies depending on the underlying nutrient deficiency and the severity of the condition. Common symptoms shared across these forms of nutritional anemia include fatigue, weakness, pallor, and exertional dyspnea, reflecting the reduced oxygen-carrying capacity of the blood due to decreased RBC production. Iron-deficiency anemia often presents with additional signs such as brittle nails, spoon-shaped nails (koilonychia), and angular cheilitis (cracks or sores at the corners of the mouth) due to the systemic effects of iron deficiency on various tissues. In severe cases, patients may develop pica, an unusual craving for non-food substances such as ice, clay, or starch, which may further exacerbate the underlying iron deficiency. Vitamin B12 deficiency anemia and folate deficiency anemia may present with neurological symptoms similar to those seen in megaloblastic anemia, including paresthesia's, peripheral neuropathy, gait disturbances, and cognitive impairment. However, these neurological manifestations are generally less pronounced compared to megaloblastic anemia, reflecting the milder impact of vitamin B12 or folate deficiency on nerve tissues in the absence of megaloblastic changes in the bone marrow.

Megaloblastic anemia and nutritional anemia exhibit distinct clinical presentations, influenced by the underlying nutrient deficiency and the severity of the condition. While megaloblastic anemia is characterized by neurological manifestations in addition to typical symptoms of anemia, nutritional anemia presents with a broader spectrum of signs reflecting the systemic effects of specific nutrient deficiencies. Recognizing these differences in clinical presentation is crucial for accurate diagnosis and timely intervention to prevent complications and improve patient outcomes.

IV. Treatment

Effective management of megaloblastic anemia and nutritional anemia involves addressing the underlying nutrient deficiency through targeted supplementation and dietary modifications tailored to the individual patient's needs.

A. Megaloblastic Anemia

Treatment of megaloblastic anemia primarily revolves around replenishing deficient vitamin B12 or folate levels to restore normal erythropoiesis and prevent neurological complications.

- Vitamin B12 Supplementation: For patients with vitamin B12 deficiency, treatment typically involves intramuscular or subcutaneous injections of hydroxocobalamin or cyanocobalamin. These parenteral forms of vitamin B12 bypass the gastrointestinal absorption pathway and ensure rapid and effective repletion of vitamin B12 stores. Following an initial loading dose, maintenance therapy may involve regular injections at specified intervals based on the underlying cause and severity of the deficiency.
- Folate Supplementation: Folate deficiency anemia is treated with oral folate supplementation, typically in the form of folic acid tablets. Folic acid is readily absorbed in the small intestine and effectively replenishes folate stores, promoting erythropoiesis and normalizing red blood cell production. Unlike vitamin B12 deficiency, folate deficiency can be corrected through oral supplementation alone, with dosages adjusted based on the severity of the deficiency and the patient's response to treatment.

To specific nutrient supplementation, management of megaloblastic anemia may also involve addressing associated complications such as neurological manifestations. Patients with severe neurological symptoms or irreversible nerve damage may require additional interventions such as physical therapy, occupational therapy, or supportive care to optimize functional outcomes and quality of life.

B. Nutritional Anemia

- The management of nutritional anemia varies depending on the underlying nutrient deficiency involved, with specific treatment strategies targeting iron, vitamin B12, or folate deficiency.
- Iron Supplementation: Iron-deficiency anemia is treated with oral or intravenous iron supplementation to replenish depleted iron stores and restore hemoglobin synthesis. Oral iron supplements such as ferrous sulfate or ferrous gluconate are commonly prescribed as first-line therapy for mild to moderate cases of iron deficiency anemia. However, intravenous iron may be necessary for patients with severe iron deficiency, intolerance to oral iron therapy, or malabsorption disorders.
- Vitamin B12 Supplementation: Vitamin B12 deficiency anemia is managed similarly to megaloblastic anemia, with intramuscular or subcutaneous injections of vitamin B12 (hydroxocobalamin or cyanocobalamin) to restore

depleted vitamin B12 stores and normalize red blood cell production. Like megaloblastic anemia, maintenance therapy may involve regular injections based on the underlying cause and severity of the deficiency.

- Folate Supplementation: Folate deficiency anemia is treated with oral folate supplementation, typically in the form of folic acid tablets, to replenish deficient folate levels and promote erythropoiesis. Oral folate supplementation is effective for correcting folate deficiency, with dosages adjusted based on the severity of the deficiency and the patient's response to treatment.

To nutrient supplementation, management of nutritional anemia may also involve dietary modifications to ensure adequate intake of iron, vitamin B12, and folate-rich foods. Patient education plays a crucial role in promoting dietary adherence and optimizing long-term outcomes in nutritional anemia.

V. Result & Discussion

We have made important observations about the differences between megaloblastic anemia and nutritional anemia as well as their respective clinical outcomes from our comparative investigation. Deficits in vitamin B12 or folate are the main cause of megaloblastic anemia, as they impede the synthesis of DNA and the maturation of red blood cells.

Clinical Feature	Megaloblastic Anemia	Nutritional Anemia
Fatigue	Present	Present
Weakness	Present	Present
Pallor	Present	Present
Neurological Symptoms	Present (especially severe in cases of vitamin B12 deficiency)	Less pronounced
Other Symptoms	Neurological manifestations such as paresthesia's, memory impairment	Varies depending on the specific nutrient deficiency

Table 1. Summarizes the Comparative Evaluation of Clinical Symptoms

Conversely, iron, vitamin B12, and folate shortages impair erythropoiesis and the synthesis of hemoglobin; these deficiencies are included in nutritional anemia. Megaloblastic anemia presents clinically as weakness, weariness, pallor, and neurological symptoms, particularly in situations of acute vitamin B12 insufficiency.



Figure 3. Graphical Representation of Comparative Evaluation of Clinical Symptoms

Conversely, the range of symptoms associated with nutritional anemia varies according on the particular nutrient deficiency. In megaloblastic anemia, laboratory results show hyper segmented neutrophils, macrocytic red blood cells, and particular biochemical abnormalities that may be related to a folate or vitamin B12 deficit. On the other hand, microcytic or macrocytic red blood cells, as well as accompanying changes in serum iron, vitamin B12, or folate levels, are characteristics of nutritional anemia.

Complication	Megaloblastic Anemia	Nutritional Anemia
Hematologic Complications	Pancytopenia, increased susceptibility to infections	Increased susceptibility to infections, bleeding disorders
Neurological Complications	Peripheral neuropathy, subacute combined degeneration of the spinal cord	Mild cognitive impairment, neurological deficits in severe cases
Cardiovascular Complications	Not common	Heart failure in severe cases of iron-deficiency anemia

Table 2. Summarizes the Comparative Complication Occurred By Deficiency

Treatment approaches vary; for megaloblastic anemia, therapies for neurological problems must be combined with vitamin B12 or folate supplements. The management of nutritional anemia involves correcting underlying vitamin deficits through parenteral or oral supplementation, along with necessary dietary modifications. With the right care, the prognosis for both kinds of anemia is usually good, leading to the resolution of symptoms and the normalization of hematologic parameters. But misdiagnosis or insufficient therapy might result in consequences including pancytopenia, cardiovascular problems, or neurological impairments.



Figure 4. Graphical Representation of Comparative Analysis of Complication Occurred by Deficiency

Cases of both types of anemia that are left untreated or improperly handled can result in consequences that affect several organ systems, highlighting the significance of early detection, focused supplementation, and close observation to minimize complications and maximize results. Our comparison analysis highlights how important it is to distinguish between megaloblastic anemia and nutritional anemia in order to provide an accurate diagnosis and provide customized care. Clinicians can improve the quality of life for patients with these common kinds of anemia and improve patient outcomes by treating underlying deficits and related consequences. To reduce the burden of anemia-related morbidity and death, more clinical trials and research are needed to improve diagnostic and treatment strategies.

VI. Conclusion

In conclusion, two common types of anemia that are defined by shortages in vital minerals necessary for erythropoiesis are megaloblastic anemia and nutritional anemia. While iron, vitamin B12, or folate deficiencies are the main causes of megaloblastic anemia, deficiencies in any of these three nutrients can also cause nutritional anemia. While weariness, weakness, and pallor are among the common symptoms, these illnesses have different clinical presentations, laboratory results, treatment approaches, prognoses, and possible consequences. Maximizing results and avoiding complications related to megaloblastic anemia and nutritional anemia require early detection, precise diagnosis, and focused treatment. Early implementation of the right supplements and dietary changes can help regulate red blood cell production, successfully refill insufficient nutritional stores, and alleviate symptoms in patients. Furthermore, to guarantee long-term success and reduce the chance of problems or recurrence, careful monitoring of the patient's reaction and adherence to treatment are required.

When it comes to teaching patients the value of proper diet, supplementation, and treatment adherence, clinicians are essential. Furthermore, to better understand the pathophysiology of nutritional anemia and megaloblastic anemia, find new treatment options, and broaden our knowledge of these hematologic illnesses, further research and clinical investigations are necessary. Healthcare practitioners can raise quality of life, lessen the burden of anemia-related morbidity and death, and improve patient outcomes by addressing the particular difficulties brought on by megaloblastic anemia and nutritional anemia. We can effectively combat these common forms of anemia and enhance public health outcomes by interdisciplinary collaboration, patient-centered treatment, and a holistic approach to management. To sum up, the area of hematology will not advance until ongoing efforts are made to increase awareness, enhance diagnostic skills, and use evidence-based interventions in order to optimize care for patients suffering from megaloblastic anemia and nutritional anemia.

References

1. *R. S. Gibson, "Principles of nutritional assessment," Oxford university press, USA, 2005.*
2. *M. J. Warren et al., "Vitamin B 12: Biosynthesis of the corrin ring," in Tetrapyrroles: Birth, Life and Death, 2009, pp. 286-299.*
3. *Gille and A. Schmid, "Vitamin B12 in meat and dairy products," Nutrition reviews, vol. 73, no. 2, pp. 106-115, 2015*
4. *Khajuria and R. Das, "Prevalence of megaloblastic anaemia and its causative factors in a tertiary care centre at Western India," Santosh University Journal of Health Sciences, vol. 8, no. 2, p. 141, 2022.*
5. *G. Nathan and F. A. Oski, "Nathan and Oski's hematology of infancy and childhood," 2003.*

6. *M. Asif Hussain et al., "Bone marrow aspiration findings in a tertiary care hospital of Peshawar," 2015.*
7. *Z. Jan, Z. Gul, and F. Liaqat, "Megaloblastic anemia and pattern of its presentation in children," Gomal Journal of Medical Sciences, vol. 14, no. 2, 2016.*
8. *S. Štifter et al., "Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma," Diagnostic pathology, vol. 5, no. 1, pp. 1-7, 2010.*
9. *S. A. Sharourou et al., "Anemia: Its prevalence, causes, and management," The Egyptian Journal of Hospital Medicine, vol. 70, no. 10, pp. 1877-1879, 2018.*
10. *Q. Wu et al., "Mechanism of megaloblastic anemia combined with hemolysis," Bioengineered, vol. 12, no. 1, pp. 6703-6712, 2021.*
11. *V. Unnikrishnan et al., "Clinico-aetiologic profile of macrocytic anemias with special reference to megaloblastic anemia," Indian Journal of Hematology and Blood Transfusion, vol. 24, pp. 155-165, 2008.*
12. *H. Wafaa et al., "Is Vitamin B12 Level a Reliable Predictor of Psychosis Severity in Male Patients with Megaloblastic Anemia at a Single Tertiary Hospital?" International Journal of General Medicine, vol. 2022, pp. 7657-7668.*
13. *M. Beckman Coulter, "Analyzer Operator's Guide," 1992.*
14. *Manual and I. Bio-Rad Quantaphase, "Folate Radioassay Kit," Bio-Rad Laboratories, Hercules, CA, 1993.*
15. *S. K. Langhani, "PREVALENCE OF SERUM FOLIC ACID DEFICIENCY AND DEMONSTRATION OF HAEMATOLOGICAL PARAMETERS AMONG POPULATION OF THARPARKAR SINDH, PAKISTAN," Journal of Peoples University of Medical & Health Sciences Nawabshah (JPUMHS), vol. 11, no. 1, pp. 105-109, 2021.*
16. *S. K. Mahajan and S. C. Aundhakar, "A study of the prevalence of serum vitamin B12 and folic acid deficiency in Western Maharashtra," Journal of family medicine and primary care, vol. 4, no. 1, pp. 64, 2015.*
17. *H. Birn et al., "Cubilin is an albumin binding protein important for renal tubular albumin reabsorption," J Clin Invest, vol. 105, no. 10, pp. 1353-1361, 2000.*
18. *Nykjaer et al., "Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D(3)," Proc Natl Acad Sci U S A, vol. 98, no. 24, pp. 13895-13900, 2001.*
19. *S. Hesdorffer and D. L. Longo, "Drug-Induced Megaloblastic Anemia," N Engl J Med, vol. 373, no. 17, pp. 1649-1658, 2015.*
20. *K. Stouten et al., "Prevalence of potential underlying aetiology of macrocytic anaemia in Dutch general practice," BMC Fam Pract, vol. 17, no. 1, pp. 113, 2016.*
21. *J. Lindenbaum et al., "Prevalence of cobalamin deficiency in the Framingham elderly population," Am J Clin Nutr, vol. 60, no. 1, pp. 2-11, 1994.*
22. *J. Norman and J. A. Morrison, "Screening elderly populations for cobalamin (vitamin B12) deficiency using the urinary methylmalonic acid assay by gas chromatography mass spectrometry," Am J Med, vol. 94, no. 6, pp. 589-594, 1993.*
23. *N. Bizzaro and A. Antico, "Diagnosis and classification of pernicious anemia," Autoimmun Rev, vol. 13, no. 4-5, pp. 565-568, 2014.*
24. *P. Gudgeon and R. Cavalcanti, "Folate testing in hospital inpatients," Am J Med, vol. 128, no. 1, pp. 56-59, 2015.*
25. *R. Green, "Vitamin B12 deficiency from the perspective of a practicing hematologist," Blood, vol. 129, no. 19, pp. 2603-2611, 2017.*